RUVBL2 and hepatocellular carcinoma: In contrast, positive cytoplasmic and nuclear immunostaining for RUVBL2 was observed in 95.4% (146/153) and 46.0% (75/153) of the HCC tumors, respectively (Fig. 3b, d and f).